Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The CATSINDO Trial in Newly Diagnosed Osteosarcoma
NCT07560826Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in osteosarcoma (OS), sponsored by Wake Forest University Health Sciences. Primary endpoint: Incidence of Dose Limiting Toxicity. Started Oct 2026; status: recruiting.
02
Drugs
methotrexate
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07560826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560826.